Baidu
map

Pediatr Pulmonol:哮喘幼儿不配合使用吸入性糖皮质激素 不妨让其看看动画片

2018-09-12 吴星 环球医学

药物依从性可能影响治疗结局。2018年9月,发表在《Pediatr Pulmonol》的一项先导研究旨在评估动画片是否会增加哮喘幼儿在吸入性糖皮质激素(ICS)给药期间的依从性。

药物依从性可能影响治疗结局。2018年9月,发表在《Pediatr Pulmonol》的一项先导研究旨在评估动画片是否会增加哮喘幼儿在吸入性糖皮质激素(ICS)给药期间的依从性。

研究对象为6~47个月诊断为哮喘且需要通过pMDI/储雾罐进行ICS治疗的幼儿,ICS每天两次,至少进行2个月。邀请在调查问卷上表示他们的孩子在治疗期间频繁哭闹或移动的家长参与到这项前瞻性交叉随机研究中。第一周的磨合期后,幼儿在ICS期间交替观看7天的动画片和另7天的黑屏视频。主要结局指标为不配合的中位时间百分比,其定义为幼儿哭闹和/或移动的时间长度除以需要ICS治疗的时间长度。

50/113名(44%)幼儿的父母表示,他们的孩子在治疗期间频繁哭闹或移动。这50名儿童中,11人(22%)完成研究。第一组,分散注意力与对照阶段不合作的中位时间百分比(IQR1~3)分别为0%(0~3)和56%(40~97),第二组对照和分散注意力阶段不合作的中位时间百分比分别为100%(98~100)和0%(0~5)。动画片可增加依从性至97%(55~100;P=0.008)。

治疗期间依从性差的哮喘幼儿可通过动画片而显著改善依从性。

原始出处:

Frémont A, Abou Taam R, Wanin S, et.al. Cartoons to improve young children's cooperation with inhaled corticosteroids: A preliminary study. Pediatr Pulmonol. 2018 Sep;53(9):1193-1199. doi: 10.1002/ppul.24070. Epub 2018 Jun 12.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1701232, encodeId=66331e01232ec, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Jan 26 02:00:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638742, encodeId=0b7d1638e4210, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Oct 18 00:00:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727588, encodeId=eba61e2758807, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat May 25 12:00:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418981, encodeId=49cc14189814f, content=<a href='/topic/show?id=4d373938e33' target=_blank style='color:#2F92EE;'>#吸入性糖皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39387, encryptionId=4d373938e33, topicName=吸入性糖皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088a3453298, createdName=listen319, createdTime=Fri Sep 14 09:00:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600355, encodeId=898a1600355d0, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Fri Sep 14 09:00:00 CST 2018, time=2018-09-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1701232, encodeId=66331e01232ec, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Jan 26 02:00:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638742, encodeId=0b7d1638e4210, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Oct 18 00:00:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727588, encodeId=eba61e2758807, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat May 25 12:00:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418981, encodeId=49cc14189814f, content=<a href='/topic/show?id=4d373938e33' target=_blank style='color:#2F92EE;'>#吸入性糖皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39387, encryptionId=4d373938e33, topicName=吸入性糖皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088a3453298, createdName=listen319, createdTime=Fri Sep 14 09:00:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600355, encodeId=898a1600355d0, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Fri Sep 14 09:00:00 CST 2018, time=2018-09-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1701232, encodeId=66331e01232ec, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Jan 26 02:00:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638742, encodeId=0b7d1638e4210, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Oct 18 00:00:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727588, encodeId=eba61e2758807, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat May 25 12:00:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418981, encodeId=49cc14189814f, content=<a href='/topic/show?id=4d373938e33' target=_blank style='color:#2F92EE;'>#吸入性糖皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39387, encryptionId=4d373938e33, topicName=吸入性糖皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088a3453298, createdName=listen319, createdTime=Fri Sep 14 09:00:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600355, encodeId=898a1600355d0, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Fri Sep 14 09:00:00 CST 2018, time=2018-09-14, status=1, ipAttribution=)]
    2019-05-25 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1701232, encodeId=66331e01232ec, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Jan 26 02:00:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638742, encodeId=0b7d1638e4210, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Oct 18 00:00:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727588, encodeId=eba61e2758807, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat May 25 12:00:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418981, encodeId=49cc14189814f, content=<a href='/topic/show?id=4d373938e33' target=_blank style='color:#2F92EE;'>#吸入性糖皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39387, encryptionId=4d373938e33, topicName=吸入性糖皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088a3453298, createdName=listen319, createdTime=Fri Sep 14 09:00:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600355, encodeId=898a1600355d0, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Fri Sep 14 09:00:00 CST 2018, time=2018-09-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1701232, encodeId=66331e01232ec, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Jan 26 02:00:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638742, encodeId=0b7d1638e4210, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Oct 18 00:00:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727588, encodeId=eba61e2758807, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat May 25 12:00:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418981, encodeId=49cc14189814f, content=<a href='/topic/show?id=4d373938e33' target=_blank style='color:#2F92EE;'>#吸入性糖皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39387, encryptionId=4d373938e33, topicName=吸入性糖皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=088a3453298, createdName=listen319, createdTime=Fri Sep 14 09:00:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600355, encodeId=898a1600355d0, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Fri Sep 14 09:00:00 CST 2018, time=2018-09-14, status=1, ipAttribution=)]

相关资讯

Respir Med:嗜伊红细胞性肉芽肿病且伴随多血管炎的过敏性患者中重度/不受控制哮喘和总生存研究

尽管哮喘、鼻炎/鼻窦炎和外周嗜酸性粒细胞事实上在所有嗜伊红细胞性肉芽肿病且伴随多血管炎(EGPA)的患者中存在,而特异性反应在这些患者中却没有很好的研究。最近,有研究人员鉴定了特异性反应对患有EGPA患者的影响。研究发现,总体来讲,33.5%(63)的患者经历了针对气源性致敏原的皮肤和/或特异性lgE测试。与气源性致敏原相关的特异性反应在22.3%的患者(占进行测试的2/3)中鉴定到,并且特异性反

阿斯利康哮喘新药tezepelumab获得美国FDA突破性疗法认定

阿斯利康和安进近日宣布,FDA授予了tezepelumab突破性疗法认定,用于治疗没有嗜酸性粒细胞表型的严重哮喘患者。阿斯利康首席医疗官肖恩·博恩(Sean Bohen)表示,这种阻断上皮细胞因子的药物是令人兴奋,因为它有可能治疗更广泛的重症哮喘患者。FDA的这一决定是基于IIb期PATHWAY研究的数据,阿斯利康和安进去年报告这项研究符合其主要临床终点。

Lancet Psychiat:儿童多动症与哮喘存在“明显”关联

英国南安普敦大学领衔开展的一项新研究发现,儿童多动症与哮喘之间存在“明显”关联,这项结果可能会对两种疾病的临床处置产生重要影响,并有望带来对多动症病理生理学的新见解。多动症,又称注意力缺陷多动障碍,是儿童时期常见的一类行为障碍,主要表现为与年龄和发育水平不相称的注意力不集中、活动过度、情绪冲动等。哮喘是一种常见的气道慢性炎症,常导致喘息、气促、胸闷等症状。南安普敦大学等机构研究人员在英国《柳叶刀·

Eur Ann Allergy Clin Immunol :过敏症对患有注意力缺陷多动障碍儿童的影响

注意力缺陷多动障碍(ADHD)在全世界范围内常见,并对那些受影响的患者造成了严重的问题。ADHD从属于过敏障碍或者过敏障碍医药治疗。ADHD和过敏均依赖于复杂的环境和遗传互作,并且它们还满足超敏反应标准。最近,有研究人员在ADHD儿童中检测了过敏的占比,包括常见的过敏障碍和过敏原,以及过敏对ADHD症状和严重度的影响。研究包括了100名患有ADHD的儿童,并进行精神病评估,从而了解ADHD类型和严

BMC Pregnancy and Childbirth:母乳喂养或能降低高风险儿童的哮喘患病率

最近发表在开放获取期刊《BMC妊娠与生育》(BMC Pregnancy and Childbirth)上的一项研究发现,如果母亲孕期使用过抗生素,孩子患哮喘的风险会升高,但如果母亲能够在孩子出生后的6个月内进行纯母乳喂养,这种风险就会被降低。

J Aller Cl Imm-Pract:哮喘、鼻窦疾病与活动性肺结核风险

由此可见,哮喘或鼻窦疾病病史可调节免疫应答,以降低成年人群中活动性结核病的发病率。

Baidu
map
Baidu
map
Baidu
map